Diabetic Retinopathy and Angiogenesis
The DOI matches its Crossref record.
Abstract
Diabetic retinopathy, a secondary microvascular complication of diabetes mellitus is the leading cause of blindness in the Unites States amongst individuals age 20 to 64. Two major retinal problems cause most of the diabetes-related vision loss: diabetic macular edema and complications from abnormal retinal blood vessel growth, angiogenesis. Secondary to angiogenesis, increased retinal blood flow is of pathogenic importance in the progression of diabetic retinopathy. Understanding the role of hyperglycemia seems to be the most critical factor in regulating retinal blood flow, as increased levels of blood glucose are thought to have a structural and physiological effect on retinal capillaries causing them to be both functionally and anatomically incompetent. High blood glucose induces hypoxia in retinal tissues, thus leading to the production of VEGF-A (vascular endothelial growth factor protein). Hypoxia is a key regulator of VEGF-induced ocular neovascularization. Secondary to the induction of VEGF by hypoxia, angiogenesis can be controlled by angiogenic inducers and inhibitors. The balance between VEGF and angiogenic inhibitors may determine the proliferation of angiogenesis in diabetic retinopathy. Since VEGF-A is a powerful angiogenic inducer, utilizing anti-VEGF treatments has proved to be a successful protocol in the treatment of proliferative diabetic retinopathy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Pathological angiogenesis: mechanisms and therapeutic strategies
Dudley, A. C., & Griffioen, A. W. (2023) · Angiogenesis · doi:10.1007/s10456-023-09876-7 · Cited by 495
Targeting Inflammation-Induced Obesity and Metabolic Diseases by Curcumin and Other Nutraceuticals
Aggarwal, B. B. (2010) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.012809.104755 · Cited by 471
Molecular Bases of VEGFR-2-Mediated Physiological Function and Pathological Role
Wang, X., Bove, A. M., Simone, G., & Ma, B. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.599281 · Cited by 442
Role of Hippo Pathway-YAP/TAZ Signaling in Angiogenesis
Boopathy, G. T. K., & Hong, W. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00049 · Cited by 344
Aronis, K. N., Chamberland, J. P., & Mantzoros, C. S. (2013) · Metabolism · doi:10.1016/j.metabol.2013.04.010 · Cited by 104
“Given the fact that angiogenesis could also have some detrimental effects (such as diabetic retinopathy (14, 15), tumor growth and metastasis (16)), we attempted to identify not only whether GLP-1 has an effect on angiogenesis but also at what doses.”
BackgroundMethodAntioxidant Phytochemicals as Potential Therapy for Diabetic Complications
Akpoveso, O.-O. P., Ubah, E. E., & Obasanmi, G. (2023) · Antioxidants · doi:10.3390/antiox12010123 · Cited by 90
“The progression from NPDR to PDR is characterized by ischemia, hypoxia, and the increased expression of proangiogenic growth factors including vascular endothelial growth factor (VEGF), fibroblast growth factor-2 (FGF-2), platelet-derived growth factor (PDGF), and angiopoietin-2 (Ang-2) which activate the growth of ab…”
BackgroundHuman retinal model systems: Strengths, weaknesses, and future directions
Eldred, K. C., & Reh, T. A. (2021) · Developmental Biology · doi:10.1016/j.ydbio.2021.09.001 · Cited by 41
Metadata
- Authors
- Crawford, T., Alfaro III, D., Kerrison, J., & Jablon, E.
- Venue
- Current Diabetes Reviews
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2009-02-01
- Volume
- 5
- Issue
- 1
- Pages
- 8-13
- ISSN
- 1573-3998 (ISSN-L)
- OpenAlex
- W2131160537
- Cited by
- 350
- References
- 0
- FWCI
- 22.49
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.